A Blog from the Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian
Dr. John Leonard Discusses Ibrutinib Combined with Chemotherapy for Patients with Follicular Lymphoma
In this video clip from OncLive Lymphoma Program Director, John Leonard, MD discusses the phase III SELENE study, which examined the addition of ibrutinib to either R-CHOP or bendamustine plus rituximab for the treatment of patients with follicular lymphoma.
Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.
View all posts by lymphomaprogram
New Developments in Lymphoma 